This work proposes to study two lung toxicants, ozone (O3) and 1-nitronaphthalene (1-NN) using a metabolomics approach. Specifically, mechanisms causing lung tolerance to repeated O3 exposure and the synergistic effects on 1-NN toxicity will be investigated. It is hypothesized that a metabolomics approach will detect changes in the metabolome corresponding to modulation of lung susceptibility to repeated O3 exposure with and without 1-NN. Analysis of these changes in metabolic phenotype will contribute to the understanding of underlying mechanisms leading to ozone tolerance and the corresponding higher lung susceptibility to 1-NN.
In specific aim (SA) 1, a time course study of O3 exposure using rats will be performed to analyze metabolic changes associated with acute O3 toxicity, repair and tolerance development. In SA 2, changes in metabolic phenotype caused by co-exposure to 1-NN will be studied at the three stages of O3 exposure; acute inflammation, resolution of initial inflammation and O3 tolerance. It is hypothesized that metabolic changes will be reflected in bronchiolar alveolar lavage fluid (BALF), as well as circulating and excreted biofluids. It is further hypothesized that metabolic markers detected in the rodent model will be indicative for O3 toxicity in non-human primates, providing a basis for a biomarker approach extendable to humans. In SA 3, BALF and plasma from O3 exposure experiments with non-human primates, obtained from a collaborator, will be analyzed and compared to the rodent model. SA 4 focuses on data analysis, interpretation and integration. The metabolomics approach includes both metabolic fingerprinting to identify novel biomarkers of toxin exposure as well as a hypothesis-driven metabolic profiling. This includes profiling of oxylipins and antioxidant levels to investigate inflammatory response and oxidative stress, phospholipid speciation in BALF to reflect compositional changes in epithelial lining fluid, and screening for common Phase II metabolites to investigate metabolite excretion.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES013933-04
Application #
7477706
Study Section
Special Emphasis Panel (ZES1-JAB-C (R1))
Program Officer
Balshaw, David M
Project Start
2005-09-01
Project End
2010-07-31
Budget Start
2008-08-01
Budget End
2009-07-31
Support Year
4
Fiscal Year
2008
Total Cost
$317,792
Indirect Cost
Name
University of California Davis
Department
Zoology
Type
Schools of Earth Sciences/Natur
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
?ervenka, L; Melenovský, V; Husková, Z et al. (2015) Inhibition of soluble epoxide hydrolase does not improve the course of congestive heart failure and the development of renal dysfunction in rats with volume overload induced by aorto-caval fistula. Physiol Res 64:857-73
Sporková, Alexandra; Jíchová, Sárka; Husková, Zuzana et al. (2014) Different mechanisms of acute versus long-term antihypertensive effects of soluble epoxide hydrolase inhibition: studies in Cyp1a1-Ren-2 transgenic rats. Clin Exp Pharmacol Physiol 41:1003-13
Xu, Dan-yan; Davis, Benjamin B; Wang, Zhen-he et al. (2013) A potent soluble epoxide hydrolase inhibitor, t-AUCB, acts through PPAR? to modulate the function of endothelial progenitor cells from patients with acute myocardial infarction. Int J Cardiol 167:1298-304
Varcabova, Sarka; Huskova, Zuzana; Kramer, Herbert J et al. (2013) Antihypertensive action of soluble epoxide hydrolase inhibition in Ren-2 transgenic rats is mediated by suppression of the intrarenal renin-angiotensin system. Clin Exp Pharmacol Physiol 40:273-81
Panigrahy, Dipak; Kalish, Brian T; Huang, Sui et al. (2013) Epoxyeicosanoids promote organ and tissue regeneration. Proc Natl Acad Sci U S A 110:13528-33
Honetschlagerova, Zuzana; Kitada, Kento; Huskova, Zuzana et al. (2013) Antihypertensive and renoprotective actions of soluble epoxide hydrolase inhibition in ANG II-dependent malignant hypertension are abolished by pretreatment with L-NAME. J Hypertens 31:321-32
Kundu, Suman; Roome, Talat; Bhattacharjee, Ashish et al. (2013) Metabolic products of soluble epoxide hydrolase are essential for monocyte chemotaxis to MCP-1 in vitro and in vivo. J Lipid Res 54:436-47
Shaik, Jafar Sadik B; Ahmad, Muzamil; Li, Wenjin et al. (2013) Soluble epoxide hydrolase inhibitor trans-4-[4-(3-adamantan-1-yl-ureido)-cyclohexyloxy]-benzoic acid is neuroprotective in rat model of ischemic stroke. Am J Physiol Heart Circ Physiol 305:H1605-13
Yang, Jun; Eiserich, Jason P; Cross, Carroll E et al. (2012) Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients. Free Radic Biol Med 53:160-71
Kopkan, Libor; Huskova, Zuzana; Sporkova, Alexandra et al. (2012) Soluble epoxide hydrolase inhibition exhibits antihypertensive actions independently of nitric oxide in mice with renovascular hypertension. Kidney Blood Press Res 35:595-607

Showing the most recent 10 out of 39 publications